vs

Side-by-side financial comparison of MEDIFAST INC (MED) and 1ST SOURCE CORP (SRCE). Click either name above to swap in a different company.

1ST SOURCE CORP is the larger business by last-quarter revenue ($113.1M vs $75.1M, roughly 1.5× MEDIFAST INC). On growth, 1ST SOURCE CORP posted the faster year-over-year revenue change (8.7% vs -36.9%). 1ST SOURCE CORP produced more free cash flow last quarter ($58.1M vs $-6.6M). Over the past eight quarters, 1ST SOURCE CORP's revenue compounded faster (7.8% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

1st Source Corporation is a financial services company headquartered in South Bend, Indiana. It operates 1st Source Bank, a bank with 81 branches in Indiana and Michigan. The bank's Specialty Finance Group provides financing for aircraft, trucks, and construction equipment. 1st Source Insurance provides insurance products and services.

MED vs SRCE — Head-to-Head

Bigger by revenue
SRCE
SRCE
1.5× larger
SRCE
$113.1M
$75.1M
MED
Growing faster (revenue YoY)
SRCE
SRCE
+45.6% gap
SRCE
8.7%
-36.9%
MED
More free cash flow
SRCE
SRCE
$64.7M more FCF
SRCE
$58.1M
$-6.6M
MED
Faster 2-yr revenue CAGR
SRCE
SRCE
Annualised
SRCE
7.8%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MED
MED
SRCE
SRCE
Revenue
$75.1M
$113.1M
Net Profit
$40.0M
Gross Margin
69.4%
Operating Margin
-10.4%
45.4%
Net Margin
35.3%
Revenue YoY
-36.9%
8.7%
Net Profit YoY
6.5%
EPS (diluted)
$-1.64
$1.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
SRCE
SRCE
Q1 26
$113.1M
Q4 25
$75.1M
$110.8M
Q3 25
$89.4M
$110.7M
Q2 25
$105.6M
$108.2M
Q1 25
$115.7M
$104.0M
Q4 24
$119.0M
$97.8M
Q3 24
$140.2M
$97.9M
Q2 24
$168.6M
$97.3M
Net Profit
MED
MED
SRCE
SRCE
Q1 26
$40.0M
Q4 25
$41.1M
Q3 25
$-2.3M
$42.3M
Q2 25
$2.5M
$37.3M
Q1 25
$-772.0K
$37.5M
Q4 24
$31.4M
Q3 24
$1.1M
$34.9M
Q2 24
$-8.2M
$36.8M
Gross Margin
MED
MED
SRCE
SRCE
Q1 26
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Operating Margin
MED
MED
SRCE
SRCE
Q1 26
45.4%
Q4 25
-10.4%
Q3 25
-4.6%
49.7%
Q2 25
-1.0%
44.5%
Q1 25
-1.1%
45.8%
Q4 24
0.6%
Q3 24
1.5%
46.3%
Q2 24
-4.7%
49.1%
Net Margin
MED
MED
SRCE
SRCE
Q1 26
35.3%
Q4 25
37.1%
Q3 25
-2.5%
38.2%
Q2 25
2.3%
34.5%
Q1 25
-0.7%
36.1%
Q4 24
32.1%
Q3 24
0.8%
35.7%
Q2 24
-4.8%
37.8%
EPS (diluted)
MED
MED
SRCE
SRCE
Q1 26
$1.63
Q4 25
$-1.64
$1.67
Q3 25
$-0.21
$1.71
Q2 25
$0.22
$1.51
Q1 25
$-0.07
$1.52
Q4 24
$0.08
$1.27
Q3 24
$0.10
$1.41
Q2 24
$-0.75
$1.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
SRCE
SRCE
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$1.3B
Total Assets
$248.0M
$9.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
SRCE
SRCE
Q1 26
Q4 25
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$162.3M
Q3 24
$170.0M
Q2 24
$163.5M
Stockholders' Equity
MED
MED
SRCE
SRCE
Q1 26
$1.3B
Q4 25
$198.9M
$1.3B
Q3 25
$214.7M
$1.2B
Q2 25
$216.0M
$1.2B
Q1 25
$211.0M
$1.2B
Q4 24
$210.1M
$1.1B
Q3 24
$207.3M
$1.1B
Q2 24
$205.3M
$1.0B
Total Assets
MED
MED
SRCE
SRCE
Q1 26
$9.1B
Q4 25
$248.0M
$9.1B
Q3 25
$268.2M
$9.1B
Q2 25
$269.3M
$9.1B
Q1 25
$280.0M
$9.0B
Q4 24
$284.2M
$8.9B
Q3 24
$291.2M
$8.8B
Q2 24
$293.5M
$8.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
SRCE
SRCE
Operating Cash FlowLast quarter
$-5.3M
$59.1M
Free Cash FlowOCF − Capex
$-6.6M
$58.1M
FCF MarginFCF / Revenue
-8.8%
51.4%
Capex IntensityCapex / Revenue
1.8%
0.9%
Cash ConversionOCF / Net Profit
1.48×
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$361.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
SRCE
SRCE
Q1 26
$59.1M
Q4 25
$-5.3M
$223.1M
Q3 25
$12.1M
$51.0M
Q2 25
$-3.4M
$44.9M
Q1 25
$3.4M
$71.8M
Q4 24
$-4.9M
$193.9M
Q3 24
$9.1M
$68.4M
Q2 24
$13.1M
$50.0M
Free Cash Flow
MED
MED
SRCE
SRCE
Q1 26
$58.1M
Q4 25
$-6.6M
$213.0M
Q3 25
$10.8M
$47.3M
Q2 25
$-4.8M
$43.0M
Q1 25
$1.9M
$69.3M
Q4 24
$-7.2M
$181.5M
Q3 24
$7.7M
$66.7M
Q2 24
$11.1M
$46.4M
FCF Margin
MED
MED
SRCE
SRCE
Q1 26
51.4%
Q4 25
-8.8%
192.2%
Q3 25
12.0%
42.7%
Q2 25
-4.5%
39.8%
Q1 25
1.6%
66.6%
Q4 24
-6.1%
185.5%
Q3 24
5.5%
68.1%
Q2 24
6.6%
47.7%
Capex Intensity
MED
MED
SRCE
SRCE
Q1 26
0.9%
Q4 25
1.8%
9.1%
Q3 25
1.5%
3.4%
Q2 25
1.3%
1.7%
Q1 25
1.3%
2.4%
Q4 24
1.9%
12.6%
Q3 24
1.0%
1.7%
Q2 24
1.1%
3.7%
Cash Conversion
MED
MED
SRCE
SRCE
Q1 26
1.48×
Q4 25
5.42×
Q3 25
1.21×
Q2 25
-1.36×
1.20×
Q1 25
1.91×
Q4 24
6.17×
Q3 24
8.04×
1.96×
Q2 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons